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The study aimed to analyze and update the impact of pertussis on the Italian population by 
evaluating pertussis-related hospital admissions in the period 2001-2014. 
Design or methods  
Hospital Discharge Records (HDR) were provided by the National Archive of HDR data of 
the Ministry of Health. Only hospitalizations included in the primary diagnosis were 
evaluated. Significant trends over the considered years were assessed as average annual 
percent changes (AAPC) applying the Joinpoint model. 
Results 
A total of 7,102 hospital admissions for pertussis (main diagnosis) were registered; the trend 
of hospitalizations progressively decreased from >1/100,000 inhabitants in the years 2001-
2004 to 0.64/100,000 inhabitants in 2014. A great part of hospitalizations (63.6%) involved 
subjects <1 year of life; almost 20% of cases were registered in the age class 5-14 years. The 
Joinpoint analysis showed a statistically significant variation in some age classes. 
Conclusions  
Even if this study shows a decreasing trend in the number of pertussis-related hospitalizations, 
the impact of the disease in Italy in terms of hospital admissions continues to be relevant, 
especially in the <1 year age class. Pertussis therefore continues to be, in Italy as well as in 
other European countries, an important public health issue. 
 
 









Pertussis is a respiratory infection caused by Bordetella pertussis, an endemic bacteria in all 
countries, transmitted to susceptible individuals via droplets and highly contagious; it affects 
all age groups but tends to be responsible for severe clinical pictures in children, particularly 
infants (Kilgore at al., 2016; Edwards and Decker, 2013). 
It represents a worldwide important cause of childhood morbidity and mortality and, despite 
high vaccine coverage achieved in many parts of the world, it continues to be a public health 
issue (Edwards and Decker, 2013).  
In infants pertussis may have severe features, such as apnoea and cyanosis (World Health 
Organization, 2015a) while in adolescents and adults the disease is milder and it may have 
atypical features (Guiso et al., 2011a), making them a potential source of infection for 
susceptible children (World Health Organization, 2015a). 
In the pre-antibiotic and pre-vaccination era, child morbidity and mortality were very 
high(Mattoo and Cherry, 2005). 
Both whole cell (wP) and acellular (aP) pertussis vaccines have a high level of safety, efficacy 
and effectiveness (Halperin BA and Halperin SA, 2011); however aP vaccines may be less 
effective than the highest-efficacy wP vaccines (World Health Organization, 2015a). A recent 
study compared the immunity response induced by the acellular and whole cell vaccines.  
After the primary vaccination cycle, the immune response was similar in aP- and wP-
immunized children, while the Tdap booster vaccination induced lower humoral and cellular 
responses in children who were immunized with aP-vaccine compared with those vaccinated 
with wP-vaccine (van der Lee S, 2018). 
Although vaccination has been associated with a significant decrease in both incidence and 




diseases, being still a major cause of death in children <1 year of life, too young to have 
already received all their primary doses of pertussis vaccine or those whose delay the 
immunization (Halperin BA and Halperin SA, 2011; Saadatian-Elahi et al., 2016). According 
to a recent review (Domenech de Celle`s et al., 2016), the incidence of pertussis in the world 
is characterized by both spatial and temporal variability. In Europe, the notification rate has 
increased since 2011 (5.5/100,000 inhabitants) and 2012, the last epidemic year (11.6/100,000 
inhabitants and 42,525 notifications) (Tant et al., 2015; European Centre for Disease 
Prevention and Control, 2016). In 2016, the notification rate was 10.77 cases /100,000 
inhabitants, for a total of about 50,000 cases (Stefanelli et al., 2018) and in 2017 the 
confirmed European cases were 42,242 with a notification rate of 9.38/100,000 inhabitants 
(European Centre for Disease Prevention and Control, 2019).In Italy the incidence of 
pertussis has significantly decreased along with increasing immunization coverage rates. In 
the epidemic year 2012 the notification rate has been 0.82/100,000 (European Centre for 
Disease Prevention and Control, 2016) and the last avalaible data  (2017) shown 964 
notifications and a notification rate equal to 1.59/100,000 inhabitants (European Centre for 
Disease Prevention and Control, 2019). 
Extensive immunization has exerted an immunological pressure on Bordetella pertussis and 
has been followed by a relevant change of the epidemiology of this disease (Gabutti et al., 
2008). 
Noteworthy, the immune protection conferred by both natural infection and vaccination is not 
long-lasting; the decline in immunity occurs 4-12 years after vaccination. Therefore, in recent 
years it has been observed a resurgence of pertussis, due to a progressive decrease of 
immunity, in particular for acellular vaccines (Klein et al., 2012). As shown by a study on the 
seroprevalence of IgG antibodies against pertussis toxin in Italy, the limited duration of 




circulation of infection even in adulthood (Fedele et al, 2017). With the introduction of 
vaccination programs, pertussis disease has shifted to older age groups, thus involving 
adolescents and adults. 
Another significant phenomenon is the confirmation, through the surveillance systems, of B. 
pertussis strains that do not express pertactin (contained in the vaccine). This condition is 
thought to contribute to the occurrence of epidemic outbreaks registered throughout the world 
in recent years (Lam et al., 2014). 
It is believed that pertussis is widely underestimated in Italy, as well as in other countries, 
because the passive surveillance system has some critical issues such as under-notification, 
under-diagnosis and delay in notification. Besides, laboratory diagnosis is not always 
requested and most of the cases occurring in adolescents and adults with atypical presentation 
are not recognized (Guiso et al., 2011b). Laboratory confirmation and differential tests 
between Bordetella species are helpful to conferm diagnosis (Stefanelli et al, 2019) and to 
contrast the under-notification and under-diagnosis. 
The aim of this study has been to analyze and update the impact of pertussis on the Italian 
population by evaluating pertussis-related hospital admissions in the period 2001-2014. 
Methods 
The Hospital Discharge Record (HDR) was officially established in 1991 with the aim of 
providing a summary of the main information contained in the medical record (Decree of the 
Ministry of Health of 28 December 1991).  
HDRs represent the information gathering tool for each patient discharged by public and 
private hospital and contains information on clinical and organizational aspects of 
hospitalization (Decree of the Ministry of Health of 28 December 1991) and are coded by the 
International Classification of Disease, 9th Revision, Clinical Modification Coding System 




All anonymous HDRs data were provided by the National Archive of HDR data of the 
Ministry of Health; for this type of retrospective study formal consent was not required. This 
survey is not based upon animal or human clinical study nor patient data. Anyway, the 
research was performed protecting any personal data accordingly to the Helsinki Declaration 
and to the Italian law (Legislative Decree of 30 June 2003).  
Only hospitalizations included in the primary diagnosis and containing the following ICD9-
CM diagnosis codes were evaluated: 033.0 (pertussis caused by Bordetella pertussis), 033.1 
(pertussis caused by Bordetella parapertussis), 033.8 (pertussis caused by other specified 
organisms), 033.9 (pertusiss caused by unspecified organisms) and 484.3 (pneumonia in 
pertussis). The patient identification code was not requested. 
Data processing was performed through the Microsoft Excel 2007 Software. The calculation 
of rates was performed using the resident population data available for each considered year 
in the National Statistics Institute (ISTAT) website. 
Significant trends over the considered years were assessed as average annual percent changes 
(AAPC). This is a summary measure of the trend over a given fixed interval that is computed 
as a weighted average of the annual percent change (APC) emerging from the joinpoint 
model, using weights equating to the length of the APC interval. If an AAPC lies entirely 
within a single joinpoint segment, the AAPC is the same as the APC for that segment (Kim et 
al., 2000).  
Results 
In the studied period (2001-2014) a total of 7,102 hospital admissions for pertussis (main 
diagnosis) were registered in the database provided by the Ministry of Health. 
The trend of hospitalizations showed a peak in 2002, when 15.1% (1,074 hospitalizations) of 




had obviously the same trend and progressively decreased from values >1/100,000 inhabitants 
in the years 2001-2004 to 0.64/100,000 inhabitants in 2014 (Figure 1). 
In the study period, the overall annual pertussis hospitalization rate was 0.87 per 100,000 
inhabitants showing a significant reduction trend [AAPC: -7.5% (95% CI: -10.1; -4.8)]. The 
age group with the highest hospitalization rate regarded children under 1 year of age. During 
the studied period this age group showed an average annual rate of 59.7 per 100,000 
inhabitants, shifting from 67.1 in 2001 to 57.4 in 2014 with a significant reduction trend 
[AAPC: -4.9% (95% CI: -8.0; -1.7)] and peaking in 2002 with 118.7 hospitalizations per 
100,000 populations. The peak in 2002 was highlighted for all age classes considered. In the 
last three years, the trend of pertussis hospitalization rate for children up to 15 years of age 
reversed even if it isn't statistically significant in all the age class considered; the more 
relevant increase concerned the children under 1 year of age for which the rate of 
hospitalization rose from 41.6 per 100,000 in 2011 to 57.6 per 100,000 inhabitants in 2014 
(APCC 10.9, CI95%: -6.2 – 31.1, not significant). Overall, the distribution pattern of 
hospitalization stratified by age group resulted quite similar during the studied period (Figure 
2).  
Taking into account the different ICD9-CM diagnosis codes used, 60.4% of the admissions 
during the period considered were pertussis caused by unspecified organisms, 31.2% pertussis 
caused by Bordetella pertussis, 3.4% pertussis caused by Bordetella parapertussis, 2.7% 
pertussis pneumonia and 2.3% pertussis caused by other specified organisms. As we do not 
have additional data concerning laboratory tests, we are unsure why in many cases 033.8 or 
033.9 was coded. For both diagnoses, pertussis caused by non-specified organisms and 
pertussis caused by Bordetella pertussis, the trend of the percentage of hospitalizations is 





Most hospitalizations (6,457 cases; 90.9% of all hospitalizations) were ordinary admissions 
(general ward) and 645 (9.1%) were day-hospital admissions. Females were more represented 
than men (53.3% vs. 46.7%) [statistically significant AAPC Female: -7,4% (CI95%: -10,6; -
4,6) Male: -7.4 (CI95%: -10.1 –  -4.7), Figure 3]. 
Noteworthy, hospitalization was urgent in 78.4% of cases and the urgency is greater in the 
first age class than in all the others. The duration of stay was less than one week for most 
admissions (73.8%) (Figure 4). The mean was 5.77 (5.67-5.89), the median was 5 days (5%-
95% boundaries: 5% 1 days and 95%: 14 days).  
Most hospitalized patients were discharged at home (90.2%), followed by voluntary dismissal 
in 7.06% of cases; nine patients died (0.13%), aged between 61 and 94 and just in one case <1 
year of age, 2 patients (0.03) were discharged at a health care provision, 23 patients (0.32) 
were discharged at home with activation of home care, 150 patients (2.11) were transferred to 
another acute care institution, 10 patiens (0.14) were transferred to the same institution for 
another type of hospitalization or other hospitalization regimen, 1 patient (0.01) was 
transferred to a rehabilitation institute.   
The analysis of hospitalizations stratified by geographical area showed a wide range of 
hospitalization rates in different regions; the highest rates were registered in Sicily, Apulia 
and Campania (3.79, 3.76 and 3.74/100,000 in 2002, respectively), in Sardinia (3.29/100,000 
in 2004) and in Valle d'Aosta (4.74/100,000 in 2012) (Table 1).  
Discussion 
This study investigated the impact of pertussis in Italy in terms of hospitalization, thus 
assessing the most serious cases of the disease. The rate of hospitalization during the studied 





As expected, the rate of hospitalization in <1 year-old children was particularly high 
(59.4/100,000). These data confirm that pertussis continues to be a major public health 
problem for the most vulnerable subjects, such as unvaccinated or not completely immunized 
infants and children, possibly exposed to adolescents and adults who act as an often 
unidentified source of infection (Zamir et al., 2015). 
The age distribution of pertussis detected in this study is in line with the one reported in the 
scientific literature. In a study conducted in Israel in 2015, <1 year-old children showed a 5-
fold higher notification rate than the other age groups (96/100,000 inhabitants) and were the 
most involved age group in hospitalization (Zamir et al., 2015). 
This scenario agrees with what was reported in Australia in 2011, where pertussis was 
reported three times more frequently in children than in the general population. In particular, 
1-2 months of age children showed a notification rate 3.5 times higher than the one registered 
in 3-11 months-old children (Foxwell et al., 2011). 
A study in Catalonia showed an incidence rate of pertussis (1.56/100,000 inhabitants / year) 
and a hospitalization rate (0.85/100,000 inhabitants in the period 2004-2008) (Crespo et al., 
2011). This later increased in recent years (1.01/100,000 inhabitants in period 2012-2013) 
(Crespo et al., 2015). The proportion of hospitalizations compared to the notifications was 
equal to 31.5%. More than half of the notified cases of illness (52.9%) and 93.7% of 
admissions occurred in <1 year-old children, confirming also in this geographical area the 
greater involvement of this age group. 
Taking into account the notifications (Figure 1S, Supplementary Material) (European Centre 
for Disease Prevention and Control, 2016; European Centre for Disease Prevention and 
Control, 2017; Epicentro, 2018a) and hospital admissions registered in Italy in the period 





This value could be likely related to the quite high under-notification of the disease. A recent 
study supports this evaluation showing that Italian physicians rarely suspect pertussis in adult 
or in elderly patients with long-lasting cough and usually request a diagnostic test 
(Gonfiantini et al., 2013).  
The poor use of laboratory tests as confirmation of a suspected infection caused by Bordetella 
pertussis lowers the possibility of diagnosis in patients of all ages with an atypical 
presentation of the illness and contributes to under-notification and under-diagnosis 
(Gonfiantini et al., 2014; Crespo et al., 2015). In Sweden only 2% of all laboratory confirmed 
hospitalized pertussis cases are above one year and younger than 20 year of age; in our study 
there could be a limit in the evaluation of hospitalizations considering the absence of 
laboratory diagnosis (Aronsson et al, 2018).  
It should also be noted that in Italy, in recent years, there has also been a decrease in vaccine 
coverage (VC) rate for pertussis; in fact, while in 2007-2008 a VC of 96.7% was achieved, in 
2014 VC felt to 94.6%, reaching the minimum value of 93.3% in 2015 (Figure 1S 
Supplementary Material) (Epicentro, 2018b). However, an improvement in VC is occurring 
both in childhood and adolescence as effect of the vaccination requirement  (Ministero della 
Salute, 2018; Law 31 July 2017 N.119).   
In the present study, most hospitalizations lasted about a week, accordingly to another study 
conducted in Piedmont in 2013. Besides, the authors of this study underlined the usefulness of 
vaccination for mother during the post-partum period and for other family members with 
close contact with the baby, called cocoon strategy, as they could be a potential source of 
infection; they believed that cocoon strategy could reduce the transmission of the disease and 
consequently also of the pertussis-related hospitalizations, in particular in <1 year of age 
children (Meregaglia et al., 2013). However, in recent years this strategy has not been 




family contacts (this strategy could be effective provided that a large number of contacts is 
immunized) and some cost –effectiveness assessments not always favorable. A study 
conducted in the USA, in fact, recognized the vaccination in pregnancy with a dose of dTap 
(diphtheria, tetanus, acellular pertussis with a reduced antigen content) as more cost-effective 
than the cocoon strategy (Terranella et al., 2013) and also WHO considers vaccination of 
pregnant women as more cost-effective than "cocoon strategy" (World Health Organization 
2015b).  
In accordance with what is reported in the literature, a booster dose of acellular pertussis 
vaccine is strongly recommended in order to overcome the decline in immunity. A booster 
dose is strongly recommended in adolescents as well as every ten years in adults/elderly using 
the combined dTap vaccine, which has been approved for use in children older than 4 years of 
age (Gabutti et al., 2012; Calendario vaccinale per la vita, 2018; Vittucci et al., 2016). The 
introduction of booster doses could have impacted on hospitalizations in the 5-14 age group, 
shown in our results (Figure 2S Supplementary Material). 
Nowadays, pertussis immunization in pregnancy is strongly recommended in both the USA 
and United Kingdom and has been recently included in the National Immunization Plan in 
Italy; the objective of this intervention is the prevention of pertussis infection in infants 
(Centers for Disease Control and Prevention, 2018; Abu Raya et al., 2015; Gabutti et al., 
2015; Gabutti et al., 2017; Makis et al., 2017).  
The present study has some limitations. As a matter of fact, we evaluated pertussis-related 
hospitalizations and thus we have considered only the most severe cases of the disease. 
Besides, this observational study evaluated pertussis admissions (pertussis caused by 
Bordetella pertussis, Bordetella parapertussis, other specified organisms, unspecified 




the HDR database. This has certainly been a conservative approach and could have implied 
the loss of some cases included in the HDR database as secondary diagnosis.  
The patient identification code was not requested so we are not able to identify if any patient 
was readmitted and to estimate the duration of stay of repeated hospitalizations.  
Conclusions 
Even if this study shows a decreasing trend in the number of pertussis-related hospitalizations, 
the impact of the disease in Italy in terms of hospital admissions continues to be relevant, 
especially in the <1year age class. This impact is actually even greater taking into account 
under-notification and under-diagnosis. Pertussis therefore continues to be, in Italy as well as 
in other European countries, an important public health issue, that could even worsen as 
vaccine coverage rates are decreasing. It is therefore necessary to strengthen prevention 
activities against this relevant infectious disease by acting on multiple levels, improving the 
epidemiological surveillance, increasing the use of laboratory diagnostics for suspected cases, 
optimizing vaccine interventions already in place by improving vaccine coverage rates and 
supporting the use of already recommended booster doses in all age groups. 
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Figure 1. Absolute number and hospitalization rate per 100,000 inhabitants in the studied 
period (2001-2014). 
Figure 2. Trend of hospitalizations stratified by age class and year (AAPC: average annual 
percent changes). 
Figure 3. Trend of hospitalizations stratified by gender.Figure 4. Italian hospitalizations in 
the studied period (2001-2014) stratified by length of stay. 
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Figure 1S. Pertussis: notifications and vaccine coverage in Italy in the period 2001-2015 
(Epicentro, ECDC). 











































Table 1. Hospitalization rates by region and year (2001-2014). 
Hospitalization rate/ 
100,000  
2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 
Piedmont 1.45 1.16 0.71 0.82 0.39 0.74 0.39 0.75 0.56 0.45 0.36 0.32 0.11 0.34 
Val d'Aosta 2.51 0.00 0.00 0.00 0.00 1.61 0.80 0.00 3.15 0.00 0.78 4.74 1.56 0.00 
Lombardy 1.25 0.80 0.34 0.62 0.48 0.60 0.57 0.26 0.47 0.22 0.28 0.35 0.29 0.37 
Autonomous Province 
of Bolzano 1.30 2.37 0.00 0.85 3.35 1.24 1.44 0.40 2.00 0.20 0.39 1.39 1.18 0.19 
Autonomous Province 
of Trento 1.89 1.26 0.41 1.43 1.81 0.20 0.79 0.78 0.58 0.38 0.00 0.57 0.57 0.56 
Veneto 1.06 1.41 0.72 0.78 0.28 0.49 0.40 0.17 0.20 0.37 0.32 0.14 0.29 0.65 
Friuli Venezia Giulia 0.17 0.34 0.34 0.17 0.17 0.25 0.16 0.00 0.16 0.32 0.24 0.00 0.16 0.00 
Liguria 1.78 1.08 1.02 1.14 0.63 1.37 0.50 0.56 0.87 0.80 0.43 0.83 1.15 0.50 
Emilia Romagna 0.83 0.93 0.52 0.86 0.46 0.55 0.52 0.14 0.65 0.61 0.65 0.48 0.30 0.52 
Tuscany 0.83 1.20 0.60 0.93 0.50 0.30 0.49 0.33 0.73 0.72 0.35 0.38 0.68 0.43 
Umbria 0.85 1.69 0.60 1.06 0.93 0.69 1.03 0.00 0.00 0.67 0.33 0.34 0.00 0.22 
Marche 1.43 1.43 0.47 0.40 0.86 0.65 0.26 0.45 0.51 0.45 0.64 0.26 0.00 0.52 
Lazio 0.88 1.25 0.99 2.00 0.80 1.07 1.04 0.50 1.17 0.81 0.51 0.73 1.04 1.31 
Abruzzo 0.79 2.14 0.86 0.47 0.46 1.53 0.99 0.30 0.45 0.45 0.67 0.31 0.30 0.30 
Molise 1.56 3.12 1.56 0.31 0.93 0.31 0.00 0.00 1.56 0.00 0.00 0.00 0.32 0.00 
Campania 1.54 3.74 1.17 1.35 1.28 2.02 1.28 0.77 1.19 0.67 0.74 0.62 0.71 0.56 
Apulia 1.24 3.76 2.58 2.18 1.08 0.84 1.13 0.81 1.13 1.03 0.76 0.54 0.86 1.22 
Basilicata 0.50 0.84 1.01 0.50 0.34 0.17 0.85 0.17 0.68 0.34 0.34 0.52 0.35 0.17 
Calabria 1.79 2.54 2.04 1.14 0.55 1.15 0.45 0.40 0.85 0.90 0.55 1.02 0.36 0.25 
Sicily 1.57 3.79 2.92 1.96 1.91 1.42 1.59 1.73 1.65 1.69 1.94 1.08 0.92 1.30 
Sardinia 1.41 1.72 0.73 3.29 0.73 0.18 1.45 0.72 0.24 0.54 0.48 0.24 0.24 0.42 













Figure 1S. Pertussis: notifications and vaccine coverage in Italy in the period 2001-2015. 
Modified from: Epicentro. Pertosse: trend di notifiche in Italia, 1996-2009. 
http://www.epicentro.iss.it/problemi/pertosse/epid.asp. Accessed 22 December 2018.  
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Figure 2S.  Trend of hospitalizations in the 5-14 year age group in the period 2001-2014. 
 
